ResMed (NYSE: RMD), the Australian-based global developer, manufacturer, and distributor of medical devices is showing success to investors by not only beating EPS expectations and disclosing its 71st consecutive quarter of revenue growth, but also, and most importantly, by showing the re-establishment of its position as the leading company in the sleep apnea treatment industry in the United States.
The company in a snapshot.
a) Its third quarter report more »
ResMed (NYSE: RMD) has been a stock of interest in the community of bivio investment clubs during the past couple of years. Clubs are always looking for good, small-company stocks whose higher potential growth rates might help them beat the returns of the overall market. They've been attracted by the historical sales growth rate of ResMed, which has averaged an attractive 15.5% over the past 5 years. In more »
By Brandy Betz - January 8, 2012 | Tickers: ARAY, ACOR, A, ALGN, AMRN, AMGN, AMLN, ARTC, BIIB, BMRN, BRKR, CFN, CTRX, CELG, CNC, COV, DNDN, XRAY, EW, ENDP, EPOC, ESRX, GHDX, GILD, HLS, HTWR, HMSY, HGSI, IDXX, IPXL, INCY, IRWD, MCK, MRX, MDT, MR, MOH, MYL, NVS, ONXX, PRX, PRGO, QSII, REGN, RMD, RIGL, SGEN, ST, SIAL, THC, MDCO, THOR, VRTX, VVUS, WAT, WMGI, ZLTQ
The 30th Annual J.P. Morgan Healthcare Conference kicks off with a full day of presentations from companies that range from global pharmaceutical leaders to small cap novel pharmaceutical developers and health technology manufacturers. The majority of the presentations will be available through live webcasts with archived replay offered later in the day.